FMDV VP3 Polypeptides as TLR2 Agonists for Vaccine Adjuvants

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current compositions and methods for modulating Toll-like receptor (TLR) activity, particularly TLR2, are inadequate for effectively activating immune responses and serving as adjuvants in vaccine formulations.

Innovation Solution

The use of Foot-and-mouth disease virus (FMDV) capsid proteins VP1 and VP3, specifically the polypeptide fragments such as residues 91-150 of VP3, as TLR2 agonists to induce dendritic cell maturation and cytokine production, and their fusion with antigens like influenza matrix protein to enhance immune responses.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional TLR modulating compositions are used, then immune response activation is achieved, but the activation effectiveness is insufficient for effective adjuvant activity

Engineering Contradiction:

Improveimmune response activation effectivenessVSAvoidinsufficient adjuvant activity

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent changes the molecular structure parameters of TLR2 agonists by using specific FMDV capsid proteins (VP1, VP2, VP3) and their fragments (e.g., residues 91-150 of VP3) with defined amino acid sequences, achieving optimized immune activation effectiveness and adjuvant activity

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent creates composite vaccine formulations by combining FMDV capsid protein agonists with vaccine antigens (e.g., influenza matrix protein), where the capsid protein acts as an adjuvant component that enhances the immunogenicity of the antigen through TLR2 activation

Inventive Principle:

Principle #40Composite materials

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

VP1 and VP3 polypeptides effectively activate TLR2, leading to enhanced immune responses and adjuvant activity, demonstrated by increased cytokine production and protective effects against influenza viruses in challenge models.

Implementation Method 1

Toll-like receptors (TLRs) are pattern recognition receptors (PRRs) that recognize microbial components and endogenous ligands. TLR2 recognizes the broadest range of microbial derived agonists... VP1 and VP3 are identified herein as activators of mammalian TLR2

Methodology Applied

Scientific EffectToll-like receptor recognition:

Implementation Method 2

When binding to specific ligands, TLRs initiate rapid intracellular signaling pathways involving activation of transcription factor NFκB, MAP kinases and interferon regulatory factors, which result in innate immune activation, including production of pro-inflammatory cytokines, chemokines, interferons and immunoglobulins

Methodology Applied

Scientific EffectSignal transduction:

Data Source

PatentUS8795678B2TLR-2 agonists and methods of use thereof

Publication Date: 2014.08.05 ACAD SINICA

AI summary

Two new TLR2 agonists, VP1 and VP3, which are structural proteins of FMDV. Residues of VP3 responsible for TLR2 activation are identified. In vivo experiments showed that VP3-4xM2e is active as a vaccine adjuvant.